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short stature of a patient with 2q35-q36.2 deletion
and Waardenburg syndrome
Chuan Li1, Rongyu Chen1, Xin Fan1, Jingsi Luo1, Jiale Qian1, Jin Wang1, Bobo Xie1, Yiping Shen1,2,3* and Shaoke Chen1*Abstract
Background: Waardenburg syndrome type I (WS1), an auditory-pigmentary genetic disorder, is caused by heterozygous
loss-of-function mutations in PAX3. Abnormal physical signs such as dystopia canthorum, patchy hypopigmentation and
sensorineural hearing loss are common, but short stature is not associated with WS1.
Case presentation: We reported a 4-year and 6 month-old boy with a rare combination of WS1 and severe short stature
(83.5 cm (−5.8SD)). His facial features include dystopia canthorum, mild synophrys, slightly up-slanted palpebral
fissure, posteriorly rotated ears, alae nasi hypoplasia and micrognathia. No heterochromia was noticed. He had a
normal intelligence quotient and hearing. Insulin-like growth factor-1 (IGF-1) was 52.7 ng/ml, lower than the normal
range (55 ~ 452 ng/ml) and the peak growth hormone level was 7.57 ng/ml at 90 minutes after taking moderate
levodopa and pyridostigmine bromide. The patient exhibited a good response to human growth hormone (rhGH)
replacement therapy, showing a 9.2 cm/year growth rate and an improvement of 1 standard deviation (SD) of
height after one year treatment. CMA test of patient’s DNA revealed a 4.46 Mb de novo deletion at 2q35-q36.2
(hg19; chr2:221,234,146-225,697,363).
Conclusions: PAX3 haploinsufficiency is known to cause Waardenburg syndrome. Examining overlapping deletions in
patients led to the conclusion that EPHA4 is a novel short stature gene. The finding is supported by the splotch-retarded
and epha4 knockout mouse models which both showed growth retardation. We believe this rare condition is caused
by the haploinsufficiency of both PAX3 and EPH4 genes. We further reported a growth response to recombinant
human growth hormone treatment in this patient.
Keywords: Chromosomal microarray, 2q35-q36.2, PAX3, Waardenburg syndrome, EPHA4, Short statureBackground
Waardenburg syndrome (WS) is a group of auditory-
pigmentary genetic disorders caused by neural crest
development defects. Mutations in PAX3, a transcription
factor belonging to the family of paired-box-containing
proteins, causes WS type 1 (WS1, OMIM # 193500) and
type 3 (WS3, OMIM # 148820). WS1 and WS3 are char-
acterized by dystopia canthorum, a lateral displacement of
inner canthus of the eyes. This feature is highly penetrant
for WS1, can be objectively determined by measuring the
W indexa [1]. Hearing loss, pigmentary disturbances of
the iris, hair and skin are other common features of* Correspondence: yiping.shen@childrens.harvard.edu; chenshaoke123@163.com
1Genetic and Metabolic Central Laboratory, Guangxi Maternal and Child
Health Hospital, Nanning, GuangXi, China
Full list of author information is available at the end of the article
© 2015 Li et al.; licensee BioMed Central Ltd. T
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.Waardenburg syndrome with variable penetrance. Clin-
ically, Waardenburg syndrome can be diagnosed based
on the presence of two major features or one major fea-
ture plus two minor features [2]. Major features are sen-
sorineural hearing loss, iris pigmentary abnormality, hair
hypopigmentation, dystopia canthorum (W index > 1.95)
and affected first-degree relative. Minor features include
skin hypopigmentation, synophrys, broad nasal root,
hypoplastic alae nasi, and premature graying of the hair.
Short stature is not associated with WS1. WS3, sometimes
called Klein-Waardenburg syndrome, includes abnormal-
ities of the upper limbs in addition to dystopia canthorum,
hearing loss and changes in pigmentation. About 90% of
pathogenic variants in PAX3 are nucleotide level alter-
ations detectable by sequencing, whereas an additional
10% of WS1 are caused by large deletions involvinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Characteristic facial feature of the patient. A and B are the front and side views of the patient. Notable features include ocular hypertelorism,
dystopia canthorum, short philtrum and wide based nose root with hypoplasia alae nasi.
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be detected by karyotyping [4,5], FISH [6,7] and MLPA
[8,9]. Recently chromosomal microarray (CMA) ana-
lysis has allowed for a more accurate delineation of the
deletion interval and genes involved, allowing for better
genotype-phenotype correlation study.
Case presentation
Here we report a 4-year and 6 month-old Chinese boy
with a rare combination of Waardenburg syndrome
type 1 and severe short stature. The patient was the
first child of a non-consanguineous marriage. He had se-
vere short stature (83.5 cm (−5.8SD)) and poor weight
gain (10 kg (−4.1 SD)). Both parents had short stature but
are healthy: father’s height is 153 cm (−3.2 SD) and
mother’s height is 148 cm (−2.3SD). Patient’s short stature
is proportionate. His facial features included dystopia
canthorum (W index = 2.31), mild synophrys, slightlyTable 1 Efficacy and side-effect of the rhGH treatment
Course of GH treatment HT (cm) HT SDS (SDS) Body weight (kg
prior treatment 83.5 −5.80 10.0
1 month of therapy 85.3 −5.47 10.0
3 month of therapy 87.0 −5.17 10.5
6 month of therapy 88.3 −5.09 11.0
7 month of therapy 89.5 −5.13 11.5
8 month of therapy 89.9 −5.24 10.5
11 month of therapy 92.2 −4.83 11.5
13 month of therapy 93.3 −4.76 11.0
15 months of therapy 94.8 −4.70 11.5
9 months out of therapy 98.1 −4.80 12.0up-slanted palpebral fissure, posteriorly rotated ear, alae
nasi hypoplasia and micrognathia (Figure 1a and b). He
has normal intelligence and hearing. No heterochromia
or other pigmentation anomalies was noticed. Physical
examination did not find any other abnormalities. The
patient met the clinical diagnostic criteria of WS1. Rou-
tine blood, urine tests as well as liver and renal function
tests were all normal. Endocrine tests for TSH, FT3,
FT4, FSH, LH and insulin were normal. Insulin-like
growth factor-1 (IGF-1) was 52.7 ng/ml, lower than the
normal range (55 ~ 452 ng/ml). The peak growth hor-
mone level was 7.57 ng/ml at 90 minutes after taking
moderate levodopa and pyridostigmine bromide. Brain
MRI revealed a pituitary gland about 3.2 cm long without
abnormal morphology. Bone age based on left hand X-ray
is 1.5 years.
The patient underwent recombinant human growth
hormone (rhGH) replacement therapy for over a year.) Bone age (y) Drug dose (IU/kg) IGF-1 (ng/ml) Side-effect
1.5 - 52.7 -
- 0.11 75.8 N
- 0.11 - N
2.0 0.10 99.1 N
- 0.10 - N
- 0.11 - N
- 0.12 - N
2.0 0.12 128.0 N
- 0.12 - N
- 0.12 - N
Figure 2 Height standard deviation curve during replacement
therapy with rhGH.
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side-effect profile were monitored for at regular intervals
(Table 1). The patient exhibited a good response to rhGH
treatment. He showed a 9.2 cm/year growth rate and an
improvement of 1 SD of height after one year treatment
(Figure 2).Figure 3 Array profile of the deleted region at 2q35q36.2. The left panel is
the deleted region demarcated by the two arrows and a vertical red bar.CMA test of patient’s DNA using illumina Human SNP
cyto-12 array revealed a 4.46 Mb de novo deletion at 2q35-
q36.2 (chr2:221,234,146-225,697,363) (hg19, Figure 3).
The deletion involved the whole PAX3 gene which is re-
sponsible for the Waardenburg syndrome phenotype and
neighboring genes including EPHA4.
We evaluated previously published cases of overlap-
ping deletions with our case’s (Table 2 and Figure 4). We
noticed that two thirds of deletion cases reported short
stature or growth retardation as one of the phenotypic
features when EPHA4 gene was involved in the dele-
tions. The remaining cases did not provide height infor-
mation. The animal model supported the notion that the
EPHA4 deletion is responsible for short stature. The Spr
mutant was created by X-ray mutagenesis and character-
ized by a cytogenetically detectable deletion of band C4
on mouse chromosome 1. Heterozygous mice displayedthe whole chromosome view; the right panel is a zoomed-in view of
Table 2 The genomics and clinical presentations of previously reported deletion cases at 2q35-q36.2





stature WS related features Developmental
issues
Additional features Year reported
or database
Reference
Case 1 M 22 2q35-2q36.1
(221107075–222960879)











WS1 (DC, CHL, HI) MD, ID NA 1993 [6]
Case 3 F ? 2q35-2q36.1
(219971907–224926273)
















Case 5 F 5 2q34-q36
(209000000–231,000,000)
Short stature NA Normal
intelligence
NA 1976 [14]
Case 6 M 6 2q35-q36.2
(215300001–226100000)
<5 percentile WS3 (DC, HNA, HI, SD) Mild MD, DD, ID Normal hearing, speech and
bone age
1992 [15]
Case 7 M 4 2q35-q36.2
(215300001–226100000)
NA WS3 (DC, HNA, HI, HLM, synophrys)
blepharophimosis, a bulbous nose,
a cupid’s bow upper lip with a short
philtrum and high nasal bridge
NA NA 1998 [16]
Case 8 F 4 2q35-q36.2
(215300001–226100000)
NA WS3 (DC, HNA, HLM, Synophrys) a
cupid’s bow upper lip, a bulbous










WS1 (DC, BNR, CHL, HNA, WF) ID NA 1994 [4]
Case 10 F 5 2q35-q36
(215300001–231000000)
Short stature WS3 (CHL, HH, HI, BNR, DC,
HNA, synophrys)
Severe DD NA 1993 [5]
Case 11 F 4 2q36
(221,500,001-231,000,000)
NA WS1 (CHL, DC, HH) - Medial eyebrow flare 2013 [9]
Case 12 F infant De novo 2q36
(221,500,001-231,000,000)
IUGR Hypertelorism, hypoplastic nasal
bridge with prominent nasal tip
and anteverted nares.
DD NA 1993 [17]
Not available (NA); Waardenburg syndrome (WS); dystopia canthorum (DC); congenital hearing loss (CHL), hypoplastic nasal alae (HNA); heterochromia idiris (HI); skin depigmentation (SD); developmental delay (DD);












Figure 4 Previously published cases with overlapping deletion at 2q35-q36.2. (Each horizontal red bar represents the deletion interval of a case.
The origins of these cases are listed in Table 2).
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mentary features of WS. They also had persistent growth
retardation throughout their development [10]. The dele-
tion is approximately syntenic to human chr2:218,449,525-
232,459,056 region, both Pax3 and Epha4 were involved in
the deletion. The other Splotch mutants caused by missense
mutation (Spd) [11] or splicing mutation (Sp) [12] in Pax3
gene do not exhibit growth retardation, suggesting genes
adjacent to Pax3 are responsible for the growth retardation
phenotype. The most important evidence came from the
recent epha4 knockout mouse model. Both heterozygous
and homozygous epha4 knockout mice showed significant
postnatal growth retardation in a dose dependent manner
[13]. So far only one patient has been reported to carry a
deletion involving only the EPHA4 gene (DECIPHER
282314). It was a de novo deletion. The available pheno-
type of this patient involves the shortening of digital
bones such as short 1st metacarpal, short distal phalanx
of hallux, short distal phalanx of the 2nd finger, short
distal phalanx of the thumb, short distal phalanx of toe
and short first metatarsal. All these phenotypes were ab-
sent from either of the parents. The height information
was not available for this patient. Due to their close prox-
imity on chromosome 2, EPHA4 and PAX3 are often co-
deleted as the cases shown in Figure 4. Most of them had
reported short stature as a clinical feature [4-6,8,9,14-17].
In addition to EPHA4 and PAX3, there are about 10 more
OMIM genes involved at the deletion interval of our pa-
tient, three are associated with human diseases (AP1S3 is
associated with the susceptibility to pustular psoriasis-15;
MRPL44 is likely associated with Combined oxidative phos-
phorylation deficiency 16; CUL3 is associated with Pseudo-
hypoaldosteronism, type IIE). None of these genes or the
rest of the genes at the interval are known to be associated
with short stature. EPHA4 is not currently a known disease
causing gene. Our patient and other similar deletion pa-
tients, as well as the mouse model provide compelling evi-
dence indicating EPHA4 as a novel short stature gene.EPHA4 is a member of the EPH family of receptor tyro-
sine kinases. It was demonstrated that EPHA4 interacts dir-
ectly with growth hormone receptor (GHR) and JAK2 [11].
They form a ternary complex in human cells [11]. It is con-
ceivable that EPHA4 haploinsufficiency causes short stature
by impairing the growth hormone pathway that regulates
down-stream effectors such as STAT5B and IGF1. Segrega-
tion of the short stature phenotype with EPHA4 mutations
will further support the causal relationship.
It is interesting to note that growth hormone injection
did not improve the growth of the Epha4 homozygous
knockout mouse. In our patient, growth hormone replace-
ment therapy resulted in significant improvement of
growth velocity and height. It is not known if heterozygous
knockout mice will respond to growth hormone or not.
The response we observed in our patient provided pre-
liminary indication for rhGH treatment in patients with
EPHA4 deletion.Conclusions
The rare combination of Waardenburg syndrome pheno-
type and short stature observed in our patient can be
explained by the haploinsufficiency of both PAX3 and
EPHA4 genes involved within the deletion. Our analysis
indicated that EPHA4 is a novel short stature gene. Re-
combinant human growth hormone treatment improved
the height of the patient; suggesting that diagnosis may
help in determining utility of growth hormone in other in-
dividuals with EPHA4 associated short stature.Consent
We obtained a written consent from patient’s parent for
utilizing patient‘s clinical information, genetic details
and photos in this publication. The study is approved by
the internal review board of the Guangxi Maternal and
Child Health Hospital.
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aW index is defined as X + Y + a/b. a = inner canthal
distance; b = interpupillary distance; c = outer canthal
distance. A W index result greater than 1.95 is abnormal.
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